The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD)
Open accessAbstract
Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, is an autosomal recessive genetic disorder caused by different SMPD1 mutations. Historically, ASMD has been classified as Niemann-Pick disease (NPD) types A (NPD A) and B (NPD B). NPD A is associated with a uniformly devastating disease course, with rapidly progressing psychomotor degeneration, leading to death typically by the age of 3 years, most often from respiratory failure. In contrast, the clinical phenotype and life expectancy of patients with NPD B may vary widely. Almost all patients have hepatosplenomegaly and an atherogenic lipid profile, and most patients have interstitial lung disease with progressive impairment of pulmonary function and hematologic abnormalities including cytopenias. Other common clinical manifestations include liver dysfunction, heart disease, skeletal abnormalities and growth delays. Some patients with ASMD who survive beyond early childhood have intermediate phenotypes (variant NPD B) characterized by combinations of non-neurologic and mild to severe neurologic symptoms. The physical and psychosocial burden of illness in patients with NPD B is substantial. Common symptoms include shortness of breath, joint or limb pain, abdominal pain, bleeding and bruising. The disease often leads to chronic fatigue, limited physical or social activity and difficulties in performing daily activities or work. Many patients die before or in early adulthood, often from pneumonia/respiratory failure or liver failure. Available treatments are limited to symptom management and supportive care. An enzyme replacement therapy currently in clinical development is expected to be the first treatment addressing the underlying pathology of the disease. Early diagnosis and appropriate management are essential for reducing the risk of complications. While knowledge about ASMD is evolving, more evidence about ASMD and the natural history across the disease spectrum is needed, to improve disease recognition, timely diagnosis and appropriate disease management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lysosomal storage diseases: from pathophysiology to therapy
Parenti, G., Andria, G., & Ballabio, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-122313-085916 · Cited by 404
(2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181bd12f4 · Cited by 108
Cited by
Czubowicz, K., Jęśko, H., Wencel, P., Lukiw, W. J., & Strosznajder, R. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1448-3 · Cited by 281
Lysosomal storage disease overview
Sun, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.39 · Cited by 271
Kaddi, C. D., Niesner, B., Baek, R., Jasper, P., Pappas, J., Tolsma, J., Li, J., van Rijn, Z., Tao, M., Ortemann‐Renon, C., et al. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12304 · Cited by 36
Zheng, S., Liu, L., Liang, K., Yan, J., Meng, D., Liu, Z., Tian, S., & Shan, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06680-x · Cited by 15
Metadata
- Authors
- McGovern, M. M., Avetisyan, R., Sanson, B.-J., & Lidove, O.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2017-02-23
- Volume
- 12
- Issue
- 1
- Pages
- 41-41
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W2591036609
- Cited by
- 175
- References
- 2
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). https://app.cochat.ai/papers/10.1186/s13023-017-0572-x
- The paper
- McGovern, M. M., Avetisyan, R., Sanson, B.-J., & Lidove, O. (2017). Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-017-0572-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.